Source study found

Story checked

Human dengue trial reveals how immune memory can help—or backfire (opens in a new tab)

medicalxpress.com · 2026-11-02

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 claims go further than the study. 2 other points were not covered by the paper.

2 supported
3 overstated
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Human dengue trial reveals how immune memory can help—or backfire

medicalxpress.com · 2026-11-02

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

Three of seven claims overstate the study. Two of seven check out. Two claims the study doesn't address.

2 supported
3 overstated
2 not covered

Open claim evidence

The source study

Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses

Science Translational Medicine · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedThe study found that excessive antibody-driven viral growth exhausted the immune system, while moderate viral replication with early and balanced immune control produced the strongest and most durable immunity.View evidenceHide evidence

Why this verdict

The profile supports associations: baseline antibodies that enhanced dengue replication in vitro were linked to delayed immune activation, highest viremia, strong acute responses, and later waning of CD8+ T cells and antibodies; higher anti-NS1 antibodies were linked to early interferon/balanced activation, viremia control, and enduring B/T responses. The story’s headline-level wording turns these abstract-level associations into an unhedged causal mechanism—'antibody-driven viral growth exhausted the immune system'—and adds a 'moderate viral replication produced the strongest' formulation not established in the supplied profile. The headline therefore outruns the evidence.

Study evidence

Baseline antibodies that most efficiently increased dengue virus replication in an in vitro assay were associated with delayed inflammatory and adaptive immune activation after controlled human challenge.

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay...”

Study evidence

Participants whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies.

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies.”

Claim 2 of 7OverstatedVolunteers with one previous dengue infection had significantly higher peak viral loads than those never infected, driven by antibody-dependent enhancement, and later showed faster antibody decline and weaker sustained T-cell responses.View evidenceHide evidence

As statedsignificantly higher peak viral loads

Why this verdict

The profile supports that secondary infection status was associated with greater viremia and that an in vitro antibody-enhancement phenotype was associated with highest viremia and later waning of potent CD8+ T cells and antibodies. But the claim adds 'significantly higher peak' without abstract-level statistical detail, frames the result as driven by ADE, and appears to generalize the later waning phenotype to all volunteers with one prior dengue infection, whereas the profile ties it to the baseline in vitro enhancement phenotype.

Study evidence

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

Study evidence

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay...”

Claim 3 of 7OverstatedVolunteers with moderate viral replication mounted early antiviral responses and developed the most potent, long-lasting neutralizing antibodies and protective CD8 T-cell memory across dengue serotypes.View evidenceHide evidence

As statedpersisted for up to a year

Why this verdict

The profile supports that higher baseline anti-NS1 antibodies predicted early interferon/balanced activation, viremia control, and enduring potent B and T cell responses, and that secondary infection showed higher neutralizing antibody and protective T cell responses. However, the story’s synthesis around 'moderate viral replication' producing the 'most potent' long-lasting neutralizing antibodies and CD8 memory across serotypes is stronger and more specific than the abstract-level profile, which does not provide the claimed comparative superlative, serotype breadth for neutralizing antibodies, or detailed durability timeframe.

Study evidence

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

Study evidence

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies.”

Claim 4 of 7Not coveredThe trial was a Phase I controlled human infection clinical trial at the NIH Clinical Center in Maryland, enrolling 45 healthy adults ages 18 to 59 who were grouped by prior dengue exposure and baseline neutralizing antibodies.View evidenceHide evidence

As stated45 healthy adults ages 18 to 59

Why this verdict

The profile supports a phase 1 controlled human infection trial in 45 healthy adults stratified by dengue immune history. However, the abstract-level evidence supplied does not verify the NIH Clinical Center/Maryland setting, participant ages 18 to 59, or that participants were grouped by baseline neutralizing antibodies rather than having those antibodies measured as correlates.

Study evidence

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

Study evidence

Baseline presence of potent neutralizing antibodies together with IFN-γ+ T cells was associated with minimal viral replication after dengue virus challenge.

“individuals with potent and neutralizing antibodies and IFN-γ+ T cells at baseline experienced minimal viral replication.”

Claim 5 of 7Not coveredEvery volunteer received a single injection of a weakened DENV3 vaccine candidate and was monitored for safety, symptoms, viral load, and biomarkers over 28 days, with blood samples followed to day 365.View evidenceHide evidence

As stated28 days; day 365 follow-up

Why this verdict

The profile supports challenge with a heterotypic, full-length, attenuated dengue virus and clinical/viremia/immunogenicity monitoring. But the supplied abstract-level profile does not verify that every volunteer received a single injection, that the virus was specifically a DENV3 vaccine candidate, the 28-day monitoring window, or blood sampling through day 365.

Study evidence

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

Claim 6 of 7SupportedResearchers published a human challenge study in Science Translational Medicine examining how a person's past dengue immune history changes the body's response to infection.View evidenceHide evidence

Why this verdict

The paper profile supports that this was a controlled human dengue challenge study testing whether preexisting dengue immune history shapes viremia, clinical signs, and immunogenicity after heterotypic attenuated dengue infection. The supplied abstract-level profile does not independently verify the journal venue, but the scientific framing of the claim is supported.

Study evidence

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

Claim 7 of 7SupportedAntibodies targeting NS1 across multiple dengue serotypes were linked to earlier, more balanced immune activation and better control of the virus.View evidenceHide evidence

Why this verdict

The profile supports that higher baseline antibodies against NS1 across multiple serotypes predicted early interferon responses, balanced immune activation, viremia control, and development of enduring potent B and T cell responses. The story frames this as a linked/predictive association rather than definitive causation, which is consistent with the abstract-level evidence.

Study evidence

Higher baseline antibodies against the nonstructural protein 1 (NS1) of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells.

“higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Participants with both potent neutralizing antibodies and IFN-γ+ T cells at baseline experienced minimal viral replication after challenge.
The story discusses durable immunity and CD8 T cell memory but does not clearly report this distinct baseline correlate-of-protection finding involving potent neutralizing antibodies plus IFN-γ+ T cells.
From observational correlates analysis within interventional cohort
Important limitation: the challenge used an attenuated heterotypic dengue virus, so findings may not fully extrapolate to wild-type natural dengue infections.
The story mentions a weakened dengue virus, but the caveats supplied do not acknowledge the interpretation-changing limitation that attenuated challenge dynamics may differ from natural wild-type dengue infection.
From Phase 1 controlled human infection trial; Observational correlative analysis within a phase 1 dengue human challenge
Important limitation: many baseline biomarker findings are observational/correlative within the trial, not randomized causal tests; residual confounding and directionality concerns remain.
The story’s caveats do not mention the correlational nature of the baseline enhancement, anti-NS1, neutralizing antibody, and IFN-γ+ T cell analyses. This omission matters because several story claims use causal language such as 'driven by,' 'exhausted,' and 'produced.'
From Observational correlative analysis within a phase 1 dengue human challenge; observational predictive analysis within den

5 things the story did carry across

Core study design: phase 1 controlled human dengue challenge in 45 healthy adults testing how preexisting dengue immune history affects viremia, clinical signs, and immunogenicity after attenuated heterotypic dengue challenge.
Secondary infection status was associated with greater viremia and higher neutralizing antibody and protective T cell responses compared with primary and tertiary infection; viremia was associated with more, but still mild, clinical signs and symptoms.
Baseline antibodies that enhanced dengue replication in an in vitro assay were associated with delayed inflammatory/adaptive activation, highest viremia, strong acute responses, and later waning of potent CD8+ T cells and antibodies.
Higher baseline anti-NS1 antibodies across multiple dengue serotypes predicted early interferon responses, balanced immune activation, viremia control, and enduring potent B and T cell responses.
Important limitation: the cohort was small and phase 1, limiting precision and generalizability.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest, in a controlled human dengue virus challenge, whether preexisting immune history (primary vs secondary vs tertiary infection status) shapes viral replication (viremia), clinical signs, and immunogenicity after heterotypic attenuated dengue infection.Phase 1 controlled human infection trialExpand

In plain English

Phase 1 controlled human infection trial (n=45) tested whether preexisting dengue immune history (primary, secondary, tertiary) alters viremia, clinical signs, and immunogenicity after heterotypic, full-length, attenuated dengue virus challenge. Secondary infection status was associated with greater viremia and increased neutralizing antibody and protective T cell responses. Distinct baseline antibody profiles predicted divergent acute trajectories: baseline antibodies that enhanced in vitro replication associated with delayed immune activation, highest viremia, strong acute responses and later waning of CD8+ T cells and antibodies, whereas higher baseline anti-NS1 antibodies associated with early interferon responses, controlled viremia, and durable B and T cell responses. Individuals with potent neutralizing antibodies and IFN-γ+ T cells at baseline showed minimal viral replication. Findings are reported at abstract level from a phase 1 CHIM using an attenuated heterotypic virus.

Key findings

Secondary infection with a heterotypic attenuated dengue virus produced greater viremia and stronger neutralizing antibody and protective T cell responses than primary or tertiary infection.
Viremia was associated with increased, but overall mild, clinical signs and symptoms after challenge.

“We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection.”

What this piece can’t prove

Challenge virus was an attenuated heterotypic dengue strain; findings may not fully extrapolate to wild-type infections.
Abstract does not report detailed assay methods, sampling schedules, statistical analyses, or quantitative effect sizes and confidence intervals.

2 further details could not be confirmed from the summary.

2in vitroDetermine whether baseline antibodies that enhance dengue replication in vitro identify participants who will have delayed immune activation, higher viremia, and different downstream durability/quality of B and T cell responses.in vitro replication/enhancement assayExpand

In plain English

Baseline participant sera that most efficiently enhanced dengue virus replication in an in vitro assay identified individuals who, after controlled human challenge, had delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and subsequent waning of potent CD8+ T cells and antibodies.

Key findings

Baseline antibodies that most efficiently increased dengue virus replication in an in vitro assay were associated with delayed inflammatory and adaptive immune activation after controlled human challenge.
Those participants also experienced the highest viremia and strong acute immune responses following challenge.

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay...”

What this piece can’t prove

Findings are reported as associations between baseline in vitro activity and in vivo outcomes in the CHIM; the abstract does not present causal proof or full covariate adjustment details.

2 further details could not be confirmed from the summary.

3human in vivoDetermine whether baseline antibodies that enhance dengue replication in vitro identify participants who will have delayed immune activation, higher viremia, and different downstream durability/quality of B and T cell responses.Observational correlative analysis within a phase 1 dengue human challengeExpand

In plain English

Within a phase 1 controlled human dengue challenge (45 adults), a baseline in vitro antibody enhancement phenotype was associated with distinct post-challenge immune kinetics: greater and prolonged viral replication with delayed inflammatory and adaptive activation, strong acute responses, and later waning of potent CD8+ T cells and antibodies. By contrast, higher baseline antibodies against nonstructural protein 1 (NS1) and presence of potent neutralizing antibodies plus IFN-γ+ T cells at baseline were each associated with earlier interferon/balanced activation, viremia control, and development or maintenance of durable B and T cell responses.

Key findings

Participants whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies.
Higher baseline antibodies against nonstructural protein 1 (NS1) of multiple serotypes predicted early interferon responses, balanced immune activation, control of viremia, and development of enduring, potent B and T cell responses.

“those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies.”

What this piece can’t prove

Small phase 1 trial sample (45 participants) limits precision and generalizability.
Analysis is observational/correlative within the trial; baseline antibody phenotypes were not randomized, so residual confounding is possible.
Abstract does not report numerical effect sizes, confidence intervals, or statistical adjustment methods for the associations described.
Use of an attenuated challenge virus may not fully recapitulate wild-type dengue infection dynamics.

1 further detail could not be confirmed from the summary.

4human in vivoAssess whether higher baseline antibodies to dengue nonstructural protein 1 (NS1) across serotypes predict early interferon responses, viremia control, and enduring potent B and T cell immunity (a ‘balanced’ protective response profile).observational predictive analysis within dengue challenge cohortExpand

In plain English

In the dengue controlled human infection cohort, participants with higher baseline antibodies against dengue nonstructural protein 1 (NS1) across multiple serotypes showed a predictive association with early interferon responses, balanced immune activation, control of viremia, and development of enduring, potent B and T cell immunity.

Key findings

Higher baseline antibodies against the nonstructural protein 1 (NS1) of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells.

“higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells”

5human in vivoAssess whether participants with potent neutralizing antibodies and IFN-γ+ T cells at baseline exhibit minimal viral replication after challenge (baseline correlates of protection).observational correlates analysis within interventional cohortExpand

In plain English

In this phase 1 dengue human challenge cohort (n=45), participants who had both potent neutralizing antibodies and IFN-γ+ T cells at baseline experienced minimal viral replication after challenge, indicating these baseline immune measures correlated with protection against post-challenge viremia.

Key findings

Baseline presence of potent neutralizing antibodies together with IFN-γ+ T cells was associated with minimal viral replication after dengue virus challenge.

“individuals with potent and neutralizing antibodies and IFN-γ+ T cells at baseline experienced minimal viral replication.”

What this piece can’t prove

Small phase 1 sample (n=45) may limit precision and generalizability; abstract does not report confidence intervals or p-values for this association.
The finding is correlational (baseline predictors linked to subsequent outcome) and causal inference is limited by observational nature of this analysis within the challenge cohort.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer